<?xml version="1.0" encoding="utf-8"?>
    <rss version="2.0">
      <channel xmlns:content="http://purl.org/rss/1.0/modules/content/">
        <title>Transplant International | New and Recent Articles</title>
        <link>https://www.frontierspartnerships.org/journals/transplant-international</link>
        <description>RSS Feed for Transplant International | New and Recent Articles</description>
        <language>en-us</language>
        <generator>Frontiers Feed Generator,version:1</generator>
        <pubDate>2026-05-10T06:39:17.17+00:00</pubDate>
        <ttl>60</ttl>
        <item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.15605</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.15605</link>
        <title><![CDATA[The Critical Role of Mental Health Specialists in Organ Transplantation Teams: An ELPAT Position Statement]]></title>
        <pubdate>2026-05-08T00:00:00Z</pubdate>
        <category>Point of View</category>
        <author>Inês Mega</author><author>Manuela Almeida</author><author>Angela Buchholz</author><author>Rosie Heape</author><author>Martin Kumnig</author><author>Emma K. Massey</author><author>Mariel Nöhre</author><author>Anne Skorzewski</author><author>Hannah Maple</author>
        <description><![CDATA[Transplant patients face complex medical and psychosocial challenges that require multidisciplinary protocols and care plans. Despite this, mental health support remains varied across centers and countries, leading to unmet mental health needs. The psychological impact of transplantation is evident before and after transplantation. Transplant patients at any stage face several challenges. Non-adherence to medications is common and can be a result of the psychological burden. A transplant mental health service could address these problems and, consequently, help improve quality of life and adherence, reduce complications, and prolong graft survival. We believe this might be beneficial from an economic perspective as well, even though further research is needed. We propose a comprehensive approach based on the biopsychosocial care model for integrating specialized mental health professionals into transplant teams across all phases of care. We call upon transplant centers, medical societies, insurance providers, and policymakers to recognize the importance of mental health expertise in transplantation.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.15711</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.15711</link>
        <title><![CDATA[The Sex of Donor and Recipients in Solid Organ Transplantation: An in Depth Analysis Across the Council of Europe Member States]]></title>
        <pubdate>2026-05-07T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Emanuele Cozzi</author><author>Claudia Carella</author><author>Francesca Puoti</author><author>Lucia Masiero</author><author>John Forsythe</author><author>Derek Manas</author><author>Naomi Nathan</author><author>Artur Kaminski</author><author>Marina Álvarez</author><author>Mar Carmona</author><author>Beatriz Mahíllo</author><author>Corinne Antoine</author><author>Marta López-Fraga</author><author>Giuseppe Feltrin</author><author>Beatriz Domínguez-Gil</author>
        <description><![CDATA[Sex equity in organ donation and access to transplantation represents a key priority of the European Committee on Organ Transplantation of the Council of Europe (CD-P-TO). To increase our knowledge on sex-related differences in transplantation in the Council of Europe Member States, a specifically designed questionnaire was distributed to the CD-P-TO countries. Results confirm that, irrespective of the organ, males represent the majority of patients on the transplant waiting list. For all organs except for heart the time spent on the waiting list was shorter for men compared to women. Women represent the majority of living kidney donors (58%), whilst males are the major source of livers from living donation (54%). Across all organ types, men received 64% of deceased donor organs and 58% of living donor organs. We have found sex-related differences in transplantation activities conducted in the Council of Europe Member States. However, these may be the consequence of the higher incidence of some diseases in men, organ size mismatch, or the greater difficulty in finding immunologically compatible donors in women. At this stage, the CD-P-TO will continue its monitoring activity on this highly relevant topic and possibly extend its commitment beyond sex to include gender related aspects.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.15786</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.15786</link>
        <title><![CDATA[Present and future of liver transplantation for cholangiocellular carcinoma: moving toward personalized multiparametric transplantability patterns]]></title>
        <pubdate>2026-05-07T00:00:00Z</pubdate>
        <category>Review</category>
        <author>Umberto Cillo</author><author>Alessandro Furlanetto</author><author>Jacopo Lanari</author><author>Eleonora Nieddu</author><author>Eugenia Rosso</author><author>Francesco Enrico D’Amico</author><author>Domenico Bassi</author><author>Enrico Gringeri</author>
        <description><![CDATA[Liver transplantation for cholangiocarcinoma (CCA) shifted from a contraindication to a promising therapeutic option for selected patients. Advances in neoadjuvant therapy and refined selection criteria resulted in long-term outcomes comparable to other accepted oncologic indications, particularly in perihilar CCA managed with standardized protocols and in intrahepatic CCA with favorable tumor biology. The future challenge is to develop a multiparametric biological selection, blending clinical, functional, histopathologic, molecular, and radiologic parameters to identify candidates with indolent disease behavior, thus maximizing oncologic benefit while ensuring appropriate use of limited graft resources.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16365</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16365</link>
        <title><![CDATA[Human leukocyte antigen-incompatible living donor kidney transplantation after desensitization: experience from a major transplant centre in Mexico]]></title>
        <pubdate>2026-05-07T00:00:00Z</pubdate>
        <category>Letter to the Editor</category>
        <author>Hugo Leonardo Reynoso de la Torre</author><author>Enrique Rojas-Campos</author><author>José I. Cerrillos-Gutiérrez</author><author>Luis A. Evangelista-Carrillo</author><author>Adriana Banda-López</author><author>Moises Cruz-Landino</author><author>Laura E. Aguilar-Fletes</author><author>Luis G. González-Correa</author><author>Edith V. Alatorre-Moreno</author><author>Perla E. Simancas-Ruiz</author><author>Cindy B. Salazar López</author><author>Alejandra G. Miranda-Díaz</author><author>Sylvia Totsuka Sutto</author><author>Ernesto G. Cardona Muñoz</author><author>Mauricio Carvallo-Venegas</author><author>Salvador Mendoza-Cabrera</author><author>Claudia A. Mendoza Cerpa</author><author>Carolina Romo-Álvarez</author><author>Kevin Javier Arellano-Arteaga</author><author>Jorge Andrade-Sierra</author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16694</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16694</link>
        <title><![CDATA[Correction: Effect of normothermic machine perfusion on glycocalyx shedding during liver transplantation - a prospective pilot study]]></title>
        <pubdate>2026-05-06T00:00:00Z</pubdate>
        <category>Correction</category>
        <author>Simon Mathis</author><author>Gabriel Putzer</author><author>Lukas Gasteiger</author><author>Nikolai Staier</author><author>Lisa Schlosser</author><author>Pia Tscholl</author><author>Robert Breitkopf</author><author>Benno Cardini</author><author>Alexander Kofler</author><author>Rupert Oberhuber</author><author>Thomas Resch</author><author>Stefan Schneeberger</author><author>Judith Martini</author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16305</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16305</link>
        <title><![CDATA[Predictive biomarkers and preventive strategies for PTLD: a turning point in viro-immunologic precision medicine?]]></title>
        <pubdate>2026-05-04T00:00:00Z</pubdate>
        <category>Mini Review</category>
        <author>Sophie Caillard</author><author>Morgane Solis</author><author>Ilies Benotmane</author><author>Floriane Gallais</author><author>Samira Fafi Kremer</author>
        <description><![CDATA[Post-transplant lymphoproliferative disorders (PTLD) represent a heterogeneous group of complications with rising complexity, particularly as EBV-negative forms are increasingly recognized in adult recipients. While early EBV-driven PTLD was historically monitored by viral load, this approach fails to detect EBV-negative disease and lacks specificity even in EBV-positive cases. Recent advances in tumor immunology, virology, and liquid biopsy technologies have led to the emergence of novel biomarkers that offer improved diagnostic precision. These include plasma soluble ZEBRA antigen, reflecting lytic EBV activation; EBV DNA methylation status, which may distinguish latent from benign viral replication; and LMP1 sequence variants that influence immune evasion through the NKG2A/HLA-E axis. For EBV-negative PTLD, circulating tumor DNA profiling has shown promise for early, non-invasive detection. These innovations are complemented by preventive strategies such as anti-CD20 therapy in high-risk EBV-seronegative transplant recipients and ongoing trials of EBV-targeted vaccines. However, such approaches remain limited to EBV-naïve patients. Moving forward, integrating viral, immune, and tumor-derived markers—alongside host genetic factors—may enable more personalized surveillance and preemptive interventions. This review outlines the evolving paradigm of PTLD monitoring and highlights key areas where viro-immunologic precision medicine may reshape clinical practice.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.15985</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.15985</link>
        <title><![CDATA[Venous reconstruction in living donor liver transplantation: lessons learned from a new national program in a resource-limited setting]]></title>
        <pubdate>2026-05-04T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>K. Semash</author><author>T. Dzhanbekov</author><author>M. Nasirov</author><author>A. Subanov</author><author>B. Umarov</author>
        <description><![CDATA[Complex venous outflow reconstruction in living donor liver transplantation (LDLT) is technically demanding, particularly in resource-limited settings lacking consistent access to synthetic or cryopreserved grafts. We retrospectively analyzed 45 consecutive LDLTs performed during the initiation of a national program. Venous anatomy was evaluated using preoperative CT volumetry and intraoperative findings. Reconstruction strategies included direct anastomosis, unification venoplasty, PTFE grafts, and autologous conduits (falciform ligament, umbilical vein). Outcomes were compared between patients with (n = 17) and without (n = 28) venoplasty. Additional venous reconstruction was required in 37.8% of cases. In 6.7%, anatomically indicated veins could not be reconstructed due to lack of suitable conduits. No early venous thrombosis occurred, and all autologous conduits remained patent during follow-up. Small-for-size physiology developed in 11.1% of recipients, resolved conservatively, and was not associated with unreconstructed major veins. Major morbidity (Clavien–Dindo ≥ IIIb) occurred in 42.2%. The 90-day mortality rate was 11.1%, and 3-year survival was 82.2%, without significant differences between groups. In a newly established program within a resource-limited setting, predominantly autologous venoplasty was feasible and provided satisfactory early and mid-term outcomes.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16572</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16572</link>
        <title><![CDATA[Extended criteria deceased donor kidney transplantation in a patient with limited life expectancy]]></title>
        <pubdate>2026-05-01T00:00:00Z</pubdate>
        <category>Letter to the Editor</category>
        <author>Aisling E. Courtney</author><author>Hannah Magowan</author><author>Tim J. Brown</author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16512</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16512</link>
        <title><![CDATA[Aerial drones for graft transport — ready for takeoff?]]></title>
        <pubdate>2026-05-01T00:00:00Z</pubdate>
        <category>Letter to the Editor</category>
        <author>Benoit Mesnard</author><author>Joseph R. Scalea</author><author>Jaimmen Ketan Shah</author><author>Julien Branchereau</author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.15476</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.15476</link>
        <title><![CDATA[Impact of Early Post-Transplantation Diabetes Mellitus and Changes in Diabetic Status on Graft Failure and Mortality in Kidney Transplant Recipients]]></title>
        <pubdate>2026-04-30T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Junseok Jeon</author><author>Hye Ryoun Jang</author><author>Yebin Park</author><author>Kyungho Lee</author><author>Jung Eun Lee</author><author>Kyungdo Han</author><author>Wooseong Huh</author>
        <description><![CDATA[Post-transplantation diabetes mellitus (PTDM) is a common complication following kidney transplantation (KT), but the prognostic significance of early PTDM and changes in diabetic status remains uncertain. Using the Korean National Health Insurance Service (NHIS) database, we analyzed 8,486 KT recipients (KTRs) who underwent national health screening from 2009 to 2017. Early PTDM was defined as new-onset diabetes between 3 months and 1 year after KT. Cox regression was used to estimate the risk of graft failure and all-cause mortality. Early PTDM and preexisting DM were present in 12.2% and 28.5% of KTRs, respectively. Early PTDM was significantly associated with mortality (aHR 1.309, 95% CI 1.015–1.689) but not with graft failure. Changes in diabetic status were not significantly associated with graft failure. However, transitioning from non-DM to PTDM (aHR 1.646, 95% CI 1.080–2.510) and having persistent early PTDM (aHR 1.755, 95% CI 1.325–2.377) were associated with increased mortality, whereas regression from early PTDM to non-DM was not. Preexisting DM was associated with increased mortality, regardless of subsequent changes; the risk was relatively lower in those who regressed to non-DM. Changes in diabetic status were found to have a greater impact on outcomes than early PTDM, highlighting the importance of continuous glycemic monitoring and individualized care in KTRs.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.15409</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.15409</link>
        <title><![CDATA[Donor-Specific Blood Transfusion Induces a Transfusion-Related Early Protective Effect in Murine Lung Transplantation]]></title>
        <pubdate>2026-04-30T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Xin Jin</author><author>Charlotte Hooft</author><author>Balin Özsoy</author><author>Jan Van Slambrouck</author><author>Janne Kaes</author><author>Cedric Vanluyten</author><author>Annalisa Barbarossa</author><author>Marianne S. Carlon</author><author>Greetje Vande Velde</author><author>Mélanie Guyot</author><author>Karen Moermans</author><author>Steve Stegen</author><author>Robin Vos</author><author>Bart Vanaudenaerde</author><author>Jacques Pirenne</author><author>Laurens J. Ceulemans</author>
        <description><![CDATA[Lung transplantation (LTx) remains limited by high immunogenicity and chronic rejection, yet the application of donor-specific blood transfusion (DSBT) in LTx has not been fully investigated. We established a murine orthotopic LTx model (BALB/c to C57BL/6N) to evaluate the safety and efficacy of DSBT administered 24 h prior to transplantation. Pre-transplant transfusion was well-tolerated showing no evidence of Transfusion-Related Acute Lung Injury (TRALI) or volume-overload injury. Radiographic analysis at POD 7 demonstrated that DSBT-treated grafts maintained significantly higher aerated lung volume compared to non-transfused controls. Flow cytometric analysis at the same time point revealed that these grafts were preferentially infiltrated by recipient-derived monocytes and type 2 conventional dendritic cells (cDC2s), while lymphoid cell counts remained comparable across groups in both the lung and spleen, indicating no systemic immune depletion. By POD 35, however, histological analysis revealed that the lung grafts were extensively destroyed by severe rejection. These findings demonstrate that a 24-h pre-transplant DSBT window improves early graft patency and modulating the localized myeloid landscape in a murine model. We conclude that DSBT serves as a safe and effective induction strategy to mitigate early inflammatory consolidation, providing a predictable temporal window for secondary immunomodulatory interventions in lung transplantation.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16621</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16621</link>
        <title><![CDATA[Mesoamerican nephropathy as a potential contributor to chronic allograft dysfunction in tropical settings]]></title>
        <pubdate>2026-04-29T00:00:00Z</pubdate>
        <category>Letter to the Editor</category>
        <author>Arriel Makembi Bunkete</author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.15272</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.15272</link>
        <title><![CDATA[Back in Circulation: A Review of the Implementation of Thoracoabdominal Normothermic Regional Perfusion in Donation After Circulatory Death in Lung Transplantation]]></title>
        <pubdate>2026-04-28T00:00:00Z</pubdate>
        <category>Review</category>
        <author>Anna Niroomand</author><author>Stephanie Chang</author><author>Sandra Lindstedt</author>
        <description><![CDATA[In the face of a growing mismatch between candidates awaiting transplantation and the supply of conventional donor organs, attention has shifted toward novel methods to increase the donor pool, including the use of donation after circulatory death (DCD) and the refinement of procurement techniques that safeguard graft quality. Thoracoabdominal normothermic regional perfusion (TA-NRP) has emerged as a new strategy, leveraging extracorporeal support to curtail warm-ischemic injury while permitting in situ functional assessment. This review covers the rationale behind the use of TA-NRP, while outlining its use during procurement and the current body of evidence gathered on it implementation in lung transplantation specifically.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16266</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16266</link>
        <title><![CDATA[Long-Term Outcomes Across Age and Risk Profiles in a Caucasian Living Kidney Donor Cohort]]></title>
        <pubdate>2026-04-23T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Claudia Sommerer</author><author>Iris Schröter</author><author>Nicola Marie Kuhlmann</author><author>Zoi Bougioukou</author><author>Martin Zeier</author>
        <description><![CDATA[Living kidney donation achieves excellent recipient outcomes, but increasingly involves older and medically complex donors, while long-term data across age groups remain limited. The Heidelberg Kidney Donor Study followed 632 donors (1991–2020), stratified by age <40 (n = 93), 40–60 (n = 424), and >60 years (n = 115). Primary outcomes were a ≥50% eGFR decline and an eGFR <45 mL/min/1.73 m2 at long-term follow-up. Early post-donation adaptation, long-term eGFR trajectories, cardiovascular events, and risk patterns were evaluated. Mean donor age was 50.6 ± 10.6 years (62.5% female). eGFR declined by 26.0% after donation and remained stable thereafter. At a median follow-up of 12 years, ≥50% eGFR decline occurred in 4.8%, 5.3%, and 14.4% of donors aged <40, 40–60, and >60 years, respectively, an eGFR <45 mL/min/1.73 m2 in 1.2%, 5.3%, and 20.4%. An eGFR <30 mL/min/1.73 m2 occurred in 1.2%, major adverse cardiovascular events in 4.3%. Age, hypertension, and baseline-eGFR independently predicted renal impairment. Younger donors with hypertension or obesity had up to a 14.3% risk of ≥50% eGFR decline, exceeding the risk in healthy older donors (12.5%). Living kidney donation was associated with stable long-term kidney function after early adaptation, with substantial heterogeneity driven more by baseline renal reserve and comorbidity than chronological age alone.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16262</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16262</link>
        <title><![CDATA[Anesthetic Management of Brain-Dead Donors During Organ Retrieval: Hemodynamic Effects and Potential Organ-Protective Implications – A Retrospective Analysis of 85 Cases]]></title>
        <pubdate>2026-04-21T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Jan Sönke Englbrecht</author><author>Tobias Piegeler</author><author>Mira Küllmar</author><author>Christopher Marschall</author><author>Svitlana Ziganshyna</author>
        <description><![CDATA[Currently, no evidence-based recommendations for anesthetic management of brain-dead organ donors exist. Hemodynamic responses to surgical stimulation and potential organ-protective effects of anesthetic agents have been reported inconsistently. We retrospectively analyzed anesthetic management of all donors at University Hospital Münster between 2010 and 2025. Heart rate (HR) and mean arterial pressure (MAP) were assessed before, during, and up to 15 min after first incision. Eighty-five donors were included; volatile anesthetics were administered in 41%, opioids in 80%, and neuromuscular blocking agents in 92%. HR (bpm) remained unchanged from before (94 [85–105]) to during (93 [84–104]) and post-incision (95 [85–103]). MAP (mmHg) decreased from 5 minutes (86 [76–95]) to 15 min post-incision (80 [72–89]; p = 0.034). Sufentanil did not affect HR or MAP at any point. Sevoflurane was associated with lower HR at all time points (p < 0.001) and lower MAP during incision (p = 0.020), but independent of surgical stimulation. Anesthetic management varied substantially. Hemodynamics did not increase following incision, and our findings do not support opioid administration, whereas hemodynamic effects of sevoflurane must be carefully managed to ensure sufficient organ perfusion during retrieval. Evidence-based recommendations for anesthetic management are needed to support organ-protective strategies in organ donation.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16316</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16316</link>
        <title><![CDATA[Shaping the Future of AI in Organ Transplantation: Position Paper of the European Society for Organ Transplantation]]></title>
        <pubdate>2026-04-20T00:00:00Z</pubdate>
        <category>Position Paper</category>
        <author>Georgios Kourounis</author><author>Stephen Gilbert</author><author>Simon R. Knight</author><author>Amanda Leal</author><author>Jackie Leach Scully</author><author>Alexandre Loupy</author><author>Dominique E. Martin</author><author>Evgenia Preka</author><author>Nadia Primc</author><author>Fernando Seoane Martinez</author><author>Helena Webb</author><author>Gabriel C. Oniscu</author><author>Colin Wilson</author>
        <description><![CDATA[Advances in AI hold considerable promise for organ transplantation. While every transformation brings change, not all change is transformative. Despite the rapid growth of AI in medicine, most applications remain in developmental or experimental stages, with relatively few having been successfully integrated into routine clinical practice. As a professional society, ESOT recognises that achieving meaningful impact will require more than technical progress. This position paper outlines five critical domains for successful implementation. (1) High-quality development: Coordinated collaboration and methodological rigour are prerequisites for trust; AI is only as robust as the data used to train it. (2) Ethical considerations: We must address risks to equity and access to care, and move from generic ethical principles to transplantation-specific ethical guidance. (3) Regulatory landscape: AI in transplantation is regulated under both EU medical device and AI legislation; compliance is central to stakeholder trust. (4) Responsible adoption: AI should augment, not replace, human expertise. Strengthening AI literacy is essential for meaningful adoption. (5) Participatory design: Active involvement of transplant professionals and patients is essential to address real clinical needs. These statements serve as a strategic framework to guide clinicians, researchers, and policymakers in making AI a genuine force multiplier for the transplant community.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16632</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16632</link>
        <title><![CDATA[Exploring Tissue Expander Utility in Kidney Transplant Allograft Nephrectomy]]></title>
        <pubdate>2026-04-20T00:00:00Z</pubdate>
        <category>Letter to the Editor</category>
        <author>Ali Hosseinzadeh</author><author>Anastasios Giannou</author><author>Christopher Nguan</author><author>David Harriman</author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16100</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16100</link>
        <title><![CDATA[Time as a Therapeutic Ally: The Promise of Long-Term Solid Organ and Tissue Perfusion]]></title>
        <pubdate>2026-04-17T00:00:00Z</pubdate>
        <category>Review</category>
        <author>Florian Huwyler</author><author>Matthias Pfister</author><author>Diwakar Phuyal</author><author>Yomna E. Dean</author><author>Margareta Mittendorfer</author><author>Lars Saemann</author><author>Hannah Rasel</author><author>Simon Stoerzer</author><author>Jonas Binz</author><author>Bahareh Tabatabaei</author><author>Gabor Szabo</author><author>Sandra Lindstedt</author><author>Bahar Bassiri Gharb</author><author>Mark W. Tibbitt</author><author>Pierre-Alain Clavien</author>
        <description><![CDATA[Rapid advances in tissue preservation and the growing adoption of machine perfusion have fundamentally reshaped solid-organ and tissue transplantation in recent years. Multiple short-term perfusion devices have received regulatory approval and are increasingly used in clinical practice to preserve grafts for several hours, improving allograft assessment. The boundaries of dynamic tissue preservation have been pushed even further in research settings, where grafts have been reliably perfused for multiple days. The extended time of long-term machine perfusion opens a new therapeutic window for interventions, allowing for reconditioning and even tissue repair of injured and diseased grafts. The increasing global organ shortage makes these approaches particularly attractive to recover additional allografts for safe transplantation. In this review, we highlight current clinical practice for ex situ perfused allografts, multi-day perfusions in research settings, and potential therapeutic benefits of long-term perfusion with a focus on hearts, livers, lungs and vascularized composite allografts.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.15873</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.15873</link>
        <title><![CDATA[Totally Video-Assisted Thoracoscopic Surgery for Lung Transplantation: A Case Series]]></title>
        <pubdate>2026-04-17T00:00:00Z</pubdate>
        <category>Letter to the Editor</category>
        <author>Qiang Pu</author><author>Xiaolong Zhang</author><author>Jian Zhou</author><author>Qian Yang</author><author>Xuehua Tu</author><author>Jianrong Hu</author><author>Ningying Ding</author><author>Jiao Chen</author><author>Jun Zeng</author><author>Yuchen Huang</author><author>Jiandong Mei</author><author>Lin Ma</author><author>Chenglin Guo</author><author>Dong Tian</author><author>Lunxu Liu</author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16153</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16153</link>
        <title><![CDATA[Exploring Disease-Specific Waitlist Outcomes in Simultaneous Liver-Kidney Transplantation]]></title>
        <pubdate>2026-04-13T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Rikako Oki</author><author>Luckshi Rajendran</author><author>Dean Yonghoon Kim</author><author>Atsushi Yoshida</author><author>Marwan Abouljoud</author><author>Shunji Nagai</author>
        <description><![CDATA[The current allocation system does not account for liver etiology in simultaneous liver-kidney transplantation (SLKT). This study aims to assess differences in waitlist outcomes among major liver disease groups (alcohol-related liver disease [ALD], metabolic dysfunction-associated steatohepatitis [MASH], hepatitis C virus infection, and biliary diseases) in SLKT using Organ Procurement and Transplantation Network (OPTN) registry. In total, 4,846 adult SLKT candidates listed between January 2018 and March 2024 were enrolled. Patients with MASH had worse waitlist 1-year mortality compared to ALD adjusted for patient characteristics at listing (HR 1.300, 95% CI 1.059–1.597, p = 0.012), whereas the 1-year SLKT probability was comparable. When patients were categorized by MELD score at listing (6–20, 21–29, and ≥30), patients with MASH had significantly higher 1-year waitlist mortality compared to those with ALD in the middle MELD score group (HR 1.365, 95% CI 1.008–1.834, p = 0.044). Prior to the allocation policy change in 2020, patients with MASH experienced higher waitlist mortality compared to ALD, however, this disparity was not observed following the policy change. Waitlist outcomes varied significantly depending on the etiology in SLKT. The revised 2020 allocation policy may be temporally associated with changes in mortality disparities across different liver etiologies.]]></description>
      </item>
      </channel>
    </rss>